Evolocumab Post-Heart Attack Improves Cholesterol, Not Early Cardiovascular Events

The AMUNDSEN trial found that immediate evolocumab after a heart attack significantly improved LDL-C goal achievement at one year, reaching 82% compared to 40% with standard care. However, the study did not observe an early reduction in all-cause death or unplanned cardiovascular hospitalization within the first year. This indicates a clear benefit for cholesterol management but no immediate impact on major early cardiovascular outcomes.